

AKR1A1 RABBIT PAB

货号: S220043

产品全名: AKR1A1 兔多抗

基因符号: ALR; ARM; DD3; ALDR1

UNIPROT ID: P14550 (Gene Accession - NP_001189342)

背景: This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. This member, also known as aldehyde reductase, is involved in the reduction of biogenic and xenobiotic aldehydes and is present in virtually every tissue. Multiple alternatively spliced transcript variants of this gene exist, all encoding the same protein.

抗原: Synthetic peptide of human AKR1A1

经过测试的应用: ELISA, WB, IHC

推荐稀释比: IHC: 50-200;WB: 500-2000;ELISA: 2000-5000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse, Rat


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Metabolism, Cell Biology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human thyroid cancer tissue using 220043 (AKR1A1 Antibody) at a dilution of 1/30 (Cytoplasm, Nucleus).




In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with the synthetic peptide and then with 220043 (Anti-AKR1A1 Antibody) at dilution 1/30.



The image on the left is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using 220043 (Anti-AKR1A1 Antibody) at a dilution of 1/30.



In comparison with the IHC on the left, the same paraffin-embedded Human ovarian cancer tissue is first treated with synthetic peptide and then with D260848 (Anti-AKR1A1 Antibody) at dilution 1/30.



Gel: 10% SDS-PAGE, Lysate: 27 μ g;
Lane 1-3: Human liver cancer tissue, hela cells, 293T cells;
Primary antibody: 220043 (AKR1A1 Antibody) at dilution 1/500;
Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution;
Exposure time: 10 seconds



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
